Kura Oncology/$KURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Ticker
$KURA
Sector
Primary listing
Employees
192
Headquarters
Website
Kura Oncology Metrics
BasicAdvanced
$766M
-
-$2.26
0.40
-
Price and volume
Market cap
$766M
Beta
0.4
52-week high
$20.85
52-week low
$5.41
Average daily volume
1.9M
Financial strength
Current ratio
6.159
Quick ratio
5.928
Long term debt to equity
4.801
Total debt to equity
6.374
Interest coverage (TTM)
-138.35%
Profitability
EBITDA (TTM)
-218.828
Gross margin (TTM)
-137.89%
Net profit margin (TTM)
-236.76%
Operating margin (TTM)
-263.82%
Effective tax rate (TTM)
-1.15%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-22.93%
Return on equity (TTM)
-51.11%
Valuation
Price to revenue (TTM)
9.249
Price to book
2.51
Price to tangible book (TTM)
2.51
Price to free cash flow (TTM)
6.269
Free cash flow yield (TTM)
15.95%
Free cash flow per share (TTM)
1.408
Growth
Earnings per share change (TTM)
1.07%
3-year earnings per share growth (CAGR)
4.00%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Bulls say / Bears say
Kura recognized $14.1 million in collaboration revenue from its Kyowa Kirin partnership in Q1 2025 versus zero in Q1 2024, providing non-dilutive funding that validates its ziftomenib program and supports operations into 2027 (SEC EDGAR).
The FDA accepted Kura’s NDA for ziftomenib and granted Priority Review with a PDUFA target action date of November 30, 2025, marking significant regulatory momentum toward a potential first-in-class approval for R/R NPM1-mutant AML (GlobeNewswire).
JMP Securities reiterated a Market Outperform rating and $28 price target on April 9, 2025, citing Kura’s timely NDA submission for ziftomenib as a key catalyst for valuation upside (Investing.com).
Net loss widened to $57.4 million in Q1 2025 from $49.5 million a year earlier, highlighting escalating cash burn driven by rising R&D and G&A expenses (SEC EDGAR).
Pro forma cash declined to $630.7 million at the end of Q2 2025 from $703.2 million at the end of Q1, underscoring a narrowing runway ahead of costly Phase 3 trial initiations (SEC EDGAR).
FDA set a PDUFA action date of November 30, 2025 for ziftomenib, delaying potential revenue and extending the period of funding dependence through late 2025 (SEC EDGAR).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $766M as of September 13, 2025.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of September 13, 2025.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.